CorMedix Inc. · NASDAQ:CRMD
CorMedix — Investor Presentation (January 2023)
17 slides from CorMedix's investor presentation, January 2023

Slide 1: Corporate Presentation
Corporate Presentation January 2023

Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management’s expectations, bel

Slide 3: CorMedix is an Attractive Investment Opportunity, with Lead Product DefenCath
CorMedix is an Attractive Investment Opportunity, with Our Lead Product DefenCathTM Targeting Substantial Market Opportunities DefenCath is intended initially for CVCs used by hemodialysis patients with kidney failure to reduce the risk and incidence of catheter related blood stream infections (CRBS

Slide 4: CorMedix Executive Leadership Team
CorMedix Executive Leadership Team JO INED CO RM EDIX PRIO R EXPERIEN CE • Chief Commercial Officer of Amneal Specialty Joe Todisco 2022 • Co-founder and Chief Executive of Gemini Laboratories Chief Executive Officer • Commercial Strategy and business development at Ranbaxy • Head of Strategy at Ovi

Slide 5: Developing DefenCath: Multiple Potential Therapeutics Areas
Developing DefenCath: Multiple Potential Therapeutics Areas • No pharmacologic agents approved in the U.S. for the prevention or reduction of CRBSI in central venous catheters • DefenCath is an antimicrobial catheter lock solution designed to reduce CRBSIs and clotting • Broad antimicrobial activity

Slide 6: Catheter Related Bloodstream Infections (CRBSI) are a Common and Life-threatening Complication
Catheter Related Bloodstream Infections (CRBSI) are a Common and Life-threatening Complication of CVC use Disease Burden Health Economics ~80% of patients starting HD will have a CVC inserted for HD patients with CRBSIs have almost 2x more vascular access 1 hospitalizations per year 4 CRBSIs can occ

Slide 7: Phase 3 LOCK-IT-100 – Compelling Clinical Profile
Phase 3 LOCK-IT-100 – Compelling Clinical Profile 3 Objective to demonstrate the efficacy and safety of Interim Analysis Full Study DefenCath as a catheter lock solution for the prevention of Total CRBSIs (D / H) 28 (6 D / 22 H) 41 (9 D / 32 H) CRBSI and the incidence of treatment-emergent adverse e

Slide 8: Large Addressable Market Opportunity in Hemodialysis
Large Addressable Market Opportunity in Hemodialysis (Inpatient + Outpatient) Setting Of Care Addressable Market Reimbursement Dynamics NTAP (New Technology Add-On Payment) is an additional payment for drugs that 3mm-5mm* lumen locks per year, exceed a DRG payment amount by at least one standard dev

Slide 9: Key Takeaways from Inpatient HECON Analysis
Key Takeaways from Inpatient HECON Analysis CorMedix performed a retrospective database analysis of the largest hospital discharge database in the US, to assess the proportion of 381,336 HD-CVC patients between 2017-2021 with a diagnosis of AKI, CKD or ESRD among hospitalized inpatients, and to exam

Slide 10: NTAP, TDAPA & Separate Reimbursement
NTAP, TDAPA & Separate Reimbursement HOSPITAL INPATIENT SEPARATELY NTAP 9 New Technology Add-on Payment REIMBURSABLE Unique J Code (HCPCS Code) DefenCath application for NTAP has been reviewed favorably by CMS What is it? Additional payment for drugs that exceed a DRG payment amount by at least one

Slide 11: Commercial Execution Focus
Commercial Execution Focus Hospital (Inpatient) Dialysis Facility (Outpatient) A commercial organization of ~30 can provide A highly focused internal team of ~12 can provide adequate coverage for launch adequate coverage for launch: ~6,100 hospitals in the US, per AHA statistics There are ~7,600 dia

Slide 12: DefenCath Regulatory Status & Timeline
DefenCath Regulatory Status & Timeline • DefenCath granted Fast Track designation by FDA recognizing potential to address unmet medical need, as well as QIDP (Qualified Infectious Disease Product), which provides an additional 5 years of market exclusivity • DefenCath NDA granted rolling submission

Slide 13: DefenCath Regulatory Status & Timeline, cont.
DefenCath Regulatory Status & Timeline, cont. • CorMedix resubmitted the DefenCath NDA in February 2022, was accepted as a complete Class 2 response with a six-month review cycle and given a PDUFA Goal Date in Q3 2022 • FDA advised our CMO it would conduct a pre-approval inspection in mid-summer 202

Slide 14: DefenCath Manufacturing & Supply Chain Strategy
DefenCath Manufacturing & Supply Chain Strategy • CorMedix is pursuing a three-prong strategy to solidify our supply chain and mitigate the risk of any long-term compliance disruptions at our existing CMO or existing API supplier: • Pathway 1 – Existing CMO + Existing API Supplier – The fastest path

Slide 15: Financial Highlights
Financial Highlights Key Statistics Balance Sheet Exchange NASDAQ Global Market Cash and short-term investments* $59.0 million** Common Stock 41.3 million shares as of 11/10/2022 Debt None Market cap ~$190 million * Excluding restricted cash ** as of 9/30/2022 CONFIDENTIAL AND NOT FOR DISTRIBUTION W

Slide 16: CorMedix Key Investment Highlights
CorMedix Key Investment Highlights DefenCath is a novel product • ~80% of patients starting HD will have a CVC inserted for vascular access addressing a significant unmet • $2.3 billion spent annually on CRBSI medical need Compelling Efficacy and • 71% reduction in risk of CRBSI Safety Profile • Hig

Slide 17: References
References 1. USRDS End Stage Renal Disease 2020 Annual Data Report; Chapter 3; Vascular Access 2. Araya S. et.al.; Racial and Sex Disparities in Catheter Use and Dialysis Access in the United States Medicare Population JASN 31: 625–636, 2020 3. LOCK-IT-100: CRMD003, A Novel Tauroline-Based Catheter
Source: Internet Archive copy of cormedix.com
More decks from CorMedix Inc.
Merger or Acquisition (November 2026)7 slides · Nov 10, 2026
Merger or Acquisition (November 2026)7 slides · Nov 9, 2026
Technical Presentation (October 2026)16 slides · October 2026
CorMedix Therapeutics — Investor Presentation (September 2026)25 slides · September 2026
CorMedix Therapeutics — Investor Presentation (May 2026)24 slides · May 2026
Investor Presentation (March 2026)23 slides · Mar 6, 2026